These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 38481176

  • 1. Long-term outcomes of anti-vascular endothelial growth factor therapy with and without posterior scleral reinforcement on myopic maculopathy in myopic choroidal neovascularization eyes.
    Kang MT, Wang N, Xu W, Yusufu M, Liu W, Tian J, Qi Y.
    BMC Ophthalmol; 2024 Mar 13; 24(1):118. PubMed ID: 38481176
    [Abstract] [Full Text] [Related]

  • 2. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
    Sayanagi K, Uematsu S, Hara C, Wakabayashi T, Fukushima Y, Sato S, Ikuno Y, Nishida K.
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr 13; 257(4):749-757. PubMed ID: 30643966
    [Abstract] [Full Text] [Related]

  • 3. Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment.
    Coelho J, Ferreira A, Abreu AC, Monteiro S, Furtado MJ, Gomes M, Lume M.
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep 13; 259(9):2679-2686. PubMed ID: 33744983
    [Abstract] [Full Text] [Related]

  • 4. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P, Battaglia Parodi M, Iuliano L, Bandello F.
    Retina; 2018 Jan 13; 38(1):84-90. PubMed ID: 28098725
    [Abstract] [Full Text] [Related]

  • 5. Using optical coherence tomography angiography to guide myopic choroidal neovascularization treatment: a 3-year follow-up study.
    Ueda-Consolvo T, Shibuya N, Oiwake T, Abe S, Numata A, Honda Y, Yanagisawa S, Hayashi A.
    Graefes Arch Clin Exp Ophthalmol; 2021 Nov 13; 259(11):3295-3303. PubMed ID: 34142188
    [Abstract] [Full Text] [Related]

  • 6. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
    Matsuo M, Honda S, Matsumiya W, Kusuhara S, Tsukahara Y, Negi A.
    Eur J Ophthalmol; 2012 Nov 13; 22(2):210-5. PubMed ID: 21534251
    [Abstract] [Full Text] [Related]

  • 7. Comparison of visual prognoses between natural course of simple hemorrhage and choroidal neovascularization treated with intravitreal bevacizumab in highly myopic eyes: a 1-year follow-up.
    Goto S, Sayanagi K, Ikuno Y, Jo Y, Gomi F, Nishida K.
    Retina; 2015 Mar 13; 35(3):429-34. PubMed ID: 25166271
    [Abstract] [Full Text] [Related]

  • 8. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization.
    Oishi A, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Nakata I, Miyake M, Yoshimura N.
    Graefes Arch Clin Exp Ophthalmol; 2013 Jan 13; 251(1):1-7. PubMed ID: 22527326
    [Abstract] [Full Text] [Related]

  • 9. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
    Willis J, Morse L, Vitale S, Parke DW, Rich WL, Lum F, Cantrell RA.
    Ophthalmology; 2017 Jul 13; 124(7):935-943. PubMed ID: 28372860
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
    Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y.
    Am J Ophthalmol; 2009 Jan 13; 147(1):94-100.e1. PubMed ID: 18774550
    [Abstract] [Full Text] [Related]

  • 11. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
    Gabrielle PH, Nguyen V, Creuzot-Garcher C, Miguel L, Alforja S, Sararols L, Casaroli-Marano RP, Zarranz-Ventura J, Gillies M, Arnold J, Barthelmes D.
    Acta Ophthalmol; 2022 Feb 13; 100(1):e288-e296. PubMed ID: 33960115
    [Abstract] [Full Text] [Related]

  • 12. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P, Battaglia Parodi M, Selvi F, Parravano MC, Chiaravalloti A, Varano M, Bandello F.
    Retina; 2017 Oct 13; 37(10):1931-1941. PubMed ID: 28033235
    [Abstract] [Full Text] [Related]

  • 13. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ, Park KH, Woo SJ.
    Invest Ophthalmol Vis Sci; 2015 Sep 13; 56(10):5794-800. PubMed ID: 26325418
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH, Lee SC, Kim SH, Koh HJ, Kim SS, Byeon SH, Lee CS.
    Retina; 2017 Aug 13; 37(8):1516-1522. PubMed ID: 27798519
    [Abstract] [Full Text] [Related]

  • 16. Long-term pattern of progression of myopic maculopathy: a natural history study.
    Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W, Yasuzumi K, Nagaoka N, Saka N, Yoshida T, Tokoro T, Mochizuki M.
    Ophthalmology; 2010 Aug 13; 117(8):1595-611, 1611.e1-4. PubMed ID: 20207005
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization.
    Mandal S, Venkatesh P, Sampangi R, Garg S.
    Eur J Ophthalmol; 2007 Aug 13; 17(4):620-6. PubMed ID: 17671940
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment.
    Bae KW, Kim DI, Kim BH, Oh BL, Lee EK, Yoon CK, Park UC.
    PLoS One; 2022 Aug 13; 17(9):e0273613. PubMed ID: 36137056
    [Abstract] [Full Text] [Related]

  • 19. Is ellipsoid zone integrity essential for visual recovery in myopic neovascularization after anti-VEGF therapy?
    Milani P, Pellegrini M, Massacesi A, Moschini S, Setaccioli M, Soranna D, Zambon A, Bottoni F, Bergamini F.
    Graefes Arch Clin Exp Ophthalmol; 2017 Sep 13; 255(9):1713-1720. PubMed ID: 28667483
    [Abstract] [Full Text] [Related]

  • 20. Microvasculature Changes of Myopic Choroidal Neovascularization and the Predictive Value of Feeder Vessel Disappearance after Ranibizumab Treatment Revealed Using Optical Coherence Tomography Angiography.
    Giorno P, Iacono P, Scarinci F, Di Renzo A, Varano M, Parravano M.
    Ophthalmologica; 2020 Sep 13; 243(4):263-270. PubMed ID: 31838464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.